The expansion is part of Governor DeSantis' allocation of additional doses of the Moderna vaccine to be administered to individuals ages 65 and older.
Eligible individuals can make appointments using the online reservation system at publix.com/covidvaccine, with vaccinations starting Thursday, Jan. 14.
The announcement brings the total number of Publix pharmacies offering COVID-19 vaccinations to 105 in 12 counties.
Vaccinations are provided to eligible individuals, by appointment only, while supplies last, and at no cost to the individual. Customers with health insurance will need to bring their insurance card to their scheduled appointment.
Customers without health insurance will need to provide their driver's license or Social Security number.
This expansion comes after the company received and distributed its first shipment of vaccines.
Publix continues to communicate with the state of Florida and the other six states in its operating area to provide COVID-19 vaccinations as part of their distribution efforts.
Publix, the largest employee-owned company in the US with more than 225,000 associates, currently operates 1,264 stores in Florida, Georgia, Alabama, Tennessee, South Carolina, North Carolina and Virginia.
FDA grants priority review for GSK's gepotidacin gonorrhoea indication
GSK to receive USD370m and future royalties in CureVac/BioNTech settlement
FDA lifts pause on Valneva's chikungunya vaccine IXCHIQ for elderly, updates prescribing information
Anixa Biosciences begins US FDA approved IND transfer to support Phase 2 breast cancer vaccine trial
Pfizer and BioNTech receive EU regulatory backing for LP.8.1-adapted COVID-19 vaccine
Sanofi to acquire Vicebio for USD1.15bn to strengthen respiratory vaccine pipeline
Bavarian Nordic chikungunya vaccine enters Health Canada review process
SK bioscience submits IND for Phase 1/2 clinical trial of new influenza vaccine candidate
GC Biopharma secures Vietnamese approval for varicella vaccine BARYCELA
GSK announces submission of RSV vaccine Arexvy for FDA review
PharmaJet signs MOU with Egyptian UPA and EVA Pharma to introduce needle-free vaccine delivery
Centivax raises USD45m to commercialise universal flu vaccine
CyanVac's nasal COVID vaccine shows promise in phase 1 trial
hVIVO supports Cidara Therapeutics' positive Phase 2b influenza study results